Alterity Therapeutics (HAM:PBN) Short Interest


HAM:PBN Alterity Therapeutics Ltd HAM:PBN
34 GF Score
Price €0.34
View Full Analysis

What is Alterity Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

HAM:PBN vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Alterity Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alterity Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alterity Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Alterity Therapeutics's Short Interest falls into.


HAM:PBN
34GF Score
Alterity Therapeutics Ltd HAM:PBN
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alterity Therapeutics Business Description

Address 350 Collins Street, Suite 4, Level 14, Melbourne, VIC, AUS, 3000
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
34GF Score

Get the complete analysis for HAM:PBN

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.34
Price